Published in Gene Therapy Weekly, June 2nd, 1997
The treatment uses modified fragments of "antisense" DNA to stop the production of a cancer cell protein. This approach has worked well in reversing tumor growth in mice, and early results from the first human trials are very encouraging, the Stanford researchers report.
Dr. Branimir Sikic, professor of medicine (oncology and clinical pharmacology) at Stanford University Medical Center, presented the results of the Phase I clinical trial at the meeting of the American Society for Clinical Oncology held May 17-20 in Denver, Colorado.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.